Elan's Tysabri drug recommended by E.U. committee
: "Shares in Irish biotechnology company Elan Corp. PLC (ELN) rose 4.0% Friday on news that the scientific committee of the European Medicines Agency had recommended the return to market of its key drug, multiple sclerosis treatment Tysabri.

Analysts say Tysabri's return now looks inevitable in the E.U. - albeit on a restricted basis - and in the U.S. after last month's similar ruling by the advisory committee for the U.S. Food & Drug Administration....."